The emergency use authorizations (EUAs) for the new oral antiviral medications molnupiravir and Paxlovid(TM) (nirmatrelvir/ritonavir) supplement current therapeutic efforts to decrease hospitalizations and prevent severe COVID-19 and death. During this COCA Call, presenters from CDC, ASPR, FDA, and NIH will describe the recent EUAs and NIH treatment guidelines, patient prioritization, and resources for healthcare providers.

This video can also be viewed at